One promising strategy is to target specific antigens, as seen in MG, where CAR‐T therapy targeting B cells associated with anti‐MuSK antibodies effectively reduces autoantibody production and inflammation, leading to significant clinical improvement [43]. This evidence concerns the gene MUSK and myasthenia gravis.